Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors inside the central nervous process, conolidine modulates alternate molecular targets. A Science Advances analyze discovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7,